ULTRA-EVOLUT RCT: A Comparison of Latest-Generation TAVR Valves

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07545369

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07545369
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07545369. Randomized; no masking; primary purpose treatment. Start 2026-09-12 (anticipated); primary completion 2027-09-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ULTRA-EVOLUT RCT: A Comparison of Latest-Generation TAVR Valves
Condition
Severe Aortic Valve Stenosis
Intervention (Device)
SAPIEN 3 Ultra Resilia
Intervention (Device)
Evolut FX
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct07545369
Content hash
f986d091816cb911fbc4249060e863ebd0a2fdc3f3dd2c1a4e0cceb05aca583f